Drugstore giant CVS says it fills one of every eight retail prescriptions in the U.S. And Edward Kelly, an analyst at Credit Suisse, says the chain is filling its own prescription for success by making smart acquisitions, generating solid sales growth and bolstering its competitive advantages. The investment firm added the stock to its "focus list" on Wednesday.
CVS, which generates 70% of sales from prescription drugs, should benefit enormously from an aging population and increasing use of pharmaceuticals. As the largest drugstore chain in the country by store count (more than 5,400 at last word), the Woonsocket, R.I., company is in a strong competitive position. Its sheer size and economies of scale should enable CVS to make life difficult for smaller rivals.
CVS has been expanding through acquisitions. The Eckerd stores it acquired in 2004 represent a significant -- and underappreciated -- opportunity to boost earnings, in Kelly's view. CVS agreed earlier this year to purchase about 700 Sav-on and Osco stores from Albertsons, boosting its presence in southern California. Both deals, Kelly says, contribute to a robust earnings outlook.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In addition to operating the stores, CVS boasts a large pharmacy benefit management business. Businesses enlist PharmaCare to help provide drug coverage to insurance-plan participants. This subsidiary won a contract this week to provide mail-order, specialty-pharmacy and other services to certain employees of automaker DaimlerChrysler. Kelly says winning the contract is a defining moment for CVS because it bestows credibility on the benefit management business and sets the stage for additional wins.
The stock (symbol CVS) gained 4% on Wednesday. At $30, it trades at 19 times analysts' average earnings estimates for 2006 of $1.57 per share, according to Thomson First Call. That's an attractive price according to Kelly's analysis. He thinks the shares can rise to $35 over the next 12 months.
--Lisa Dixon
-
Stock Market Today: Have We Seen the Bottom for Stocks?Solid first-quarter earnings suggest fundamentals remain solid, and recent price action is encouraging too.
-
Is the GOP Secretly Planning to Raise Taxes on the Rich?Tax Reform As high-stakes tax reform talks resume on Capitol Hill, questions are swirling about what Republicans and President Trump will do.
-
Stock Market Today: Tariff Talks Drive Another Up-and-Down DayTrade war negotiations are happening, but the "fear gauge" is gyrating, and investors, traders and speculators are still searching for signs of a bottom.
-
Fed Leaves Rates Unchanged: What the Experts Are SayingFederal Reserve As widely expected, the Federal Open Market Committee took a 'wait-and-see' approach toward borrowing costs.
-
How to Hedge Against Trump's TariffsDonald Trump is taking action on tariffs and this could have a big impact on public companies. Here's how investors can prepare.
-
Fed Sees Fewer Rate Cuts in 2025: What the Experts Are Saying
Federal Reserve The Federal Reserve cut interest rates as expected, but the future path of borrowing costs became more opaque.
-
Why Is Warren Buffett Selling So Much Stock?Berkshire Hathaway is dumping equities, hoarding cash and making market participants nervous.
-
Fed Cuts Rates Again: What the Experts Are Saying
Federal Reserve The central bank continued to ease, but a new administration in Washington clouds the outlook for future policy moves.
-
If You'd Put $1,000 Into Google Stock 20 Years Ago, Here's What You'd Have TodayGoogle parent Alphabet has been a market-beating machine for ages.
-
Stock Market Today: Stocks Rally on Strong Netflix EarningsMega-cap tech leads the charge as markets rise for a sixth straight week.
